856-P: Efficacy and Safety of Early Treatment Intensification Guided by Glycated Albumin in Newly Diagnosed Type 2 Diabetes—A Multicentre, Randomized Clinical Trial

Le résumé fourni par la source

Introduction and Objective: To testify that knowledge of glycated albumin and adjusting anti-diabetic regimens according to GA values result in improved glycemic control in newly diagnosed type 2 diabetes mellitus (T2DM). Methods: Multicentre, Randomized Clinical Trial. Setting: 7 hospitals in China between August 2022 to August 2024. Participants: A total of 200 patients with newly diagnosed type 2 diabetes and unsatisfactory glucose control. Interventions: All the patients were 1:1 randomly assigned to two groups: GA guided therapy group and standard therapy group. In GA guided therapy group, the anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks, and all the patients were followed up for 12 weeks. Main Outcome Measures: The primary outcome was the achievement rate of HbA1c <7% at week 12. Main secondary outcomes were the achievement rate of HbA1c <6.5%, the change of HbA1c, hypoglycemia, and β-cell function. Results: A total of 200 patients were randomized. There was no significant difference in the achievement rate of HbA1c (< 7%) between GA guided therapy group (64.29%) and Standard therapy group (64.36%) after 12-week of follow-up (P=0.99). However, in Per-Protocol analysis, the achievement rate of HbA1c (< 6.5%) was significantly higher in GA guided therapy group than in Standard therapy group (40.51% vs 25.27%, P=0.03). And the change in HbA1c, HOMA-β, HOMA-IR, body weight reduction were all significantly better in GA guided therapy group than in Standard therapy group. Conclusion: In patients with newly diagnosed type 2 diabetes, the adjustment of the treatment plan according to GA does not affect the proportion of HbA1c<7% 3 months later. However, early initiation of combination therapy guided by GA may leads to further reduction in HbA1c, more improvement in HOMA β and HOMA-IR, and does not increase the risk of hypoglycemia. Disclosure Q. Ren: None. L. Ji: None. Funding Asahi Kasei Pharma Corporation

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.